Vedolizumab for crohn disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Feb 2021: Trial registered, NCT04738942
  2. 4 Jun 2021: Trial started, NCT04738942

The trials

NCT04738942: A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

State
Under way
Phase
Phase 3
People
56 taking part
Started
4 Jun 2021
Primary completion
30 May 2025
Arms
Vedolizumab 300 mg in UC cohort, Vedolizumab 300 mg in CD cohort
Results
Posted on the registry
  1. 4 Feb 2021: Trial registered
  2. 4 Jun 2021: Trial started
  3. 15 Jun 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Entyvio.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.